quinazolines has been researched along with Adverse Drug Event in 54 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.85) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (18.52) | 29.6817 |
| 2010's | 40 (74.07) | 24.3611 |
| 2020's | 3 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Brandenburg, T; Dralle, H; Führer, D; Muchalla, P; Schmid, KW; Theurer, S; Tiedje, V; Weber, F | 1 |
| Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C | 1 |
| Ahn, JS; Ahn, MJ; Chung, TY; Han, J; Jung, HA; Kang, WK; Lee, J; Lee, SH; Lim, DH; Nam, DH; Park, K; Shin, E; Sun, JM | 1 |
| Komada, F | 1 |
| Cheson, BD; Dreyling, M; Ewer, MS; Farooki, A; Fisher, RI; Goncalves, MD; Lenz, G; O'Brien, S; Yu, A; Zinzani, PL | 1 |
| Cui, J; Li, Y; Liu, R; Qi, Q; Xu, L; Zhang, Y | 1 |
| Qiu, XY; Yin, Y; Zhang, B; Zhang, YH | 1 |
| Alesini, D; Bria, E; Cantile, F; Ciardiello, F; Cortesi, E; Fasano, M; Morgillo, F; Passaro, A; Pellegrino, A | 1 |
| Bers, DM; Diecke, S; Gong, T; Knowles, JW; Lan, F; Lee, AS; Liang, P; Nguyen, PK; Robbins, RC; Sallam, K; Sanchez-Freire, V; Wang, PJ; Wang, Y; Wu, JC | 1 |
| Hunt, CM; Spraggs, CF; Xu, CF | 1 |
| Brewster, AM; Esteva, FJ; Florance, AM; Franco, SX; Hagan, MK; Perez, A; Somer, RA; Stein, S; Turner, S; Williams, W | 1 |
| Aikin, A; Balis, FM; Chuk, MK; Dombi, E; Fox, E; Lodish, M; Marcus, L; Merino, MJ; Steinberg, SM; Wells, SA; Whitcomb, PO; Widemann, BC | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Barroso-Sousa, R; de Melo Gagliato, D; Mano, MS; Santana, IA; Testa, L | 1 |
| Capdevila, J; Filetti, S; Grande, E; Kreissl, MC; Newbold, K; Reinisch, W; Robert, C; Schlumberger, M; Tolstrup, LK; Zamorano, JL | 1 |
| Amrein, PC; Berchuck, J; Deangelo, DJ; Galinsky, I; Golub, T; Neuberg, D; Sirulnik, LA; Stegmaier, K; Stone, RM; Wadleigh, M | 1 |
| Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
| Al-Kali, A; Cherry, M; Ghabache, B; Khawandanah, M; Ozer, H; Selby, G; Srour, S; Zhao, ZJ | 1 |
| He, Z; Li, G; Li, J; Lin, Y; Qiu, K; Wu, J; Zhu, J | 1 |
| Beckmann, L; Bender, R; Lange, S | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, M; Kim, SW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, KH; Lu, S; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shahidi, M; Shi, Y; Tan, EH; Tsai, CM; Yang, JC; Zazulina, V; Zhang, L | 1 |
| Dickgreber, N; Feng, J; Geater, SL; Hirsh, V; Hu, CP; Huang, Y; Lu, S; Märten, A; Massey, D; Mok, T; O'Byrne, K; Okamoto, I; Schuler, M; Sebastian, M; Sequist, LV; Shah, R; Wind, S; Wu, YL; Yamamoto, N; Yang, JC; Zhou, C | 1 |
| Chang, JC; Iqbal, A; Jakubowski, CD; Paik, PK; Plodkowski, AJ; Rekhtman, N; Yu, HA | 1 |
| Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
| Gao, B; Guo, L; Hao, S; Hu, C; Jiang, Y; Luo, D; Tian, W; Yan, J; Zhang, G; Zhang, S; Zhang, X; Zhao, J | 1 |
| Saif, MW | 1 |
| Balint, C; Bekaii-Saab, T; Campbell, A; Chen, H; Culler, K; Dai, Z; Dancey, J; Eng, C; Grever, M; Heerema, N; Lee, RM; Markowitz, J; O'Neil, B; Papp, A; Prescott, N; Sadee, W; Villalona-Calero, M; Wei, L; Zalupski, M | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Gray, J; Haura, EB; Litschauer, S; Neuger, A; Rawal, B; Schell, MJ; Simon, G; Song, L; Tanvetyanon, T; Tetteh, L; Williams, C | 1 |
| Burgers, JA; Cortesi, F; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Peters, GJ; Santoro, A; Smit, EF; Tibaldi, C; Zucali, PA | 1 |
| Franklin, G; Kalaichelvan, VK; Manavalan, R; Marslin, G; Reddy, PN; Sheeba, CJ | 1 |
| Backes, WH; Brans, B; de Langen, AJ; Dingemans, AC; Groen, HJM; Hoekstra, OS; Marcus, JT; Pruim, J; Scholtens, HTGM; Smit, EF; Thunnissen, FB; van den Boogaart, V; van Tinteren, H | 1 |
| Baselga, J; Casado, E; Cervantes, A; Chirivella, I; Elvin, P; Hamberg, P; Hoekman, K; Hurwitz, HI; Iacona, R; Jodrell, DI; Martinelli, E; Swaisland, A; Tabernero, J | 1 |
| Heigener, D; Mok, T; Reck, M; Wolf, J; Wu, YL | 1 |
| Budde, K; Glander, P; Mashreghi, MF; Matz, M; Naik, M; Neumayer, HH | 1 |
| Anagnostou, VK; Dirix, LY; Gutierrez, C; Mackey, JR; Magill, P; Migliaccio, I; Neven, P; Osborne, CK; Rimm, DL; Robert, J; Schiff, R; Sellers, M; Underhill, C | 1 |
| Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB | 1 |
| Ando, K; Asou, H; Fujisawa, S; Hotta, T; Kihara, R; Miyawaki, S; Sakura, T; Tobinai, K; Tsuboi, K; Uike, N; Watanabe, T; Yamauchi, T; Yokozawa, T | 1 |
| Cacciola, E; Cacciola, R; Candoni, A; Ciancia, R; Codeluppi, K; Crugnola, M; Grossi, A; Gugliotta, L; Iurlo, A; Liberati, AM; Lunghi, M; Martinelli, V; Mazzucconi, MG; Palmieri, F; Pierri, I; Scalzulli, PR; Specchia, G; Tieghi, A; Tortorella, G; Usala, E; Vannucchi, AM; Vianelli, N | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Burstein, HJ; Chen, WY; Downing, SR; Gelman, R; Hannagan, K; Isakoff, SJ; Klement, G; Mayer, EL; Winer, EP | 1 |
| Boshoff, C; Bulley, S; Chao, D; Falk, S; Hackshaw, A; Hatton, M; Jones, R; Khan, I; Lal, R; Lee, SM; Lewanski, C; Marshall, E; Middleton, G; Ngai, Y; Rudd, R; Skailes, G; Toy, E; Upadhyay, S; Woll, PJ | 1 |
| Bachelot, T; Campone, M; Cropet, C; Curé, H; Dalenc, F; Diéras, V; Domont, J; Ferrero, JM; Gonçalves, A; Gutierrez, M; Jimenez, M; Labbe-Devilliers, C; Le Rhun, E; Leheurteur, M; Pierga, JY; Romieu, G | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Aktan, G; Boyle, F; Buzdar, AU; Chavarri-Guerra, Y; Ejlertsen, B; Finkelstein, DM; Fumoleau, P; Goss, PE; Gradishar, W; Kaufmann, M; Lindquist, D; Martin, M; Moy, B; O'Shaughnessy, J; Piccart-Gebhart, M; Pritchard, KI; Rappold, E; Smith, IE; Williams, LS | 1 |
| Abrams, TA; Ancukiewicz, M; Bhargava, P; Blaszkowsky, LS; Duda, DG; Fuchs, CS; Jain, RK; Knowles, M; McCleary, NJ; Meyerhardt, JA; Muzikansky, A; Regan, E; Ryan, DP; Sahani, DV; Sheehan, S; Supko, JG; Vasudev, E; Zhu, AX | 1 |
| Hussar, DA | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Caligiuri, MA; Cooper, MR; Curtin, PT; DeAngelo, DJ; Druker, BJ; Heaney, ML; Heinrich, MC; Holford, N; Karol, MD; Klisovic, RB; Lecerf, JM; Nimer, SD; Paquette, RL; Sheng, S; Stone, RM | 1 |
| Kubo, K | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Chen, WP; Lee, AS; Su, MJ | 1 |
| McQueen, EG | 1 |
9 review(s) available for quinazolines and Adverse Drug Event
| Article | Year |
|---|---|
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Topics: Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Gilbert Disease; Glucuronosyltransferase; Humans; Indazoles; Lapatinib; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
Biological therapies in breast cancer: common toxicities and management strategies.
Topics: Ado-Trastuzumab Emtansine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biological Therapy; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Everolimus; Humans; Immunosuppressive Agents; Lapatinib; Maytansine; Quinazolines; Sirolimus; Trastuzumab | 2013 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Topics: Carcinoma, Neuroendocrine; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Diseases; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Piperidines; Prognosis; Quinazolines; Risk Assessment; Thyroid Neoplasms; Treatment Outcome | 2013 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Lapatinib; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab | 2015 |
Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; Humans; Lapatinib; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Risk Factors; Trastuzumab; Treatment Outcome; Withholding Treatment | 2017 |
Reviewing the safety of erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2011 |
Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation.
Topics: Calcineurin Inhibitors; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Drug Evaluation; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sirolimus; Tacrolimus; Treatment Outcome | 2011 |
[Drug-induced pulmonary edema].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Glucocorticoids; Humans; Immunosuppressive Agents; Norepinephrine; Pulmonary Edema; Quinazolines; Respiration, Artificial; Risk Factors | 2007 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
23 trial(s) available for quinazolines and Adverse Drug Event
| Article | Year |
|---|---|
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crown Ethers; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2019 |
An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Topics: Adolescent; Carcinoma, Medullary; Carcinoma, Neuroendocrine; Child; Child, Preschool; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Humans; Multiple Endocrine Neoplasia Type 2b; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Quinazolines; Thyroid Neoplasms | 2013 |
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Treatment Failure | 2014 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Humans; Janus Kinase 2; Male; Middle Aged; Phenylalanine; Polycythemia Vera; Quinazolines; Treatment Outcome; Valine | 2015 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea | 2016 |
A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Rate | 2009 |
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Dasatinib; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Vascular Endothelial Growth Factor A | 2010 |
First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tomography, Emission-Computed; Treatment Outcome | 2011 |
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzodioxoles; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Young Adult | 2010 |
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Treatment Outcome | 2011 |
A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Asian People; Aurora Kinase B; Aurora Kinases; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Neutropenia; Organophosphates; Protein Serine-Threonine Kinases; Quinazolines; Treatment Outcome | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Blood Platelets; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Methotrexate; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Piperidines; Platelet Factor 4; Proteomics; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Central Nervous System; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2 | 2013 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lapatinib; Lymph Nodes; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Marrow; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-kit; Quinazolines; Receptors, Platelet-Derived Growth Factor | 2006 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
22 other study(ies) available for quinazolines and Adverse Drug Event
| Article | Year |
|---|---|
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
Topics: Adult; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Thyroid Neoplasms; Withholding Treatment; Young Adult | 2021 |
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger | 2023 |
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.
Topics: Acrylamides; Adult; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Corneal Diseases; Drug-Related Side Effects and Adverse Reactions; Epithelium, Corneal; ErbB Receptors; Female; Humans; Immunoconjugates; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Therapies, Investigational; Vision Disorders; Visual Acuity | 2020 |
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs].
Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors | 2018 |
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Lymphoma, Non-Hodgkin; Pyrimidines; Quinazolines | 2019 |
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.
Topics: Adult; Antineoplastic Agents; Dermatitis, Phototoxic; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Piperidines; Quinazolines; Thyroid Neoplasms | 2019 |
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
Topics: Action Potentials; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic, Familial; Cell Differentiation; Cell Line; Cell Size; Cisapride; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Embryoid Bodies; Embryonic Stem Cells; Gene Expression Profiling; Genetic Predisposition to Disease; HEK293 Cells; Humans; In Vitro Techniques; Induced Pluripotent Stem Cells; Ion Channels; Kidney; Long QT Syndrome; Myocytes, Cardiac; Myofibrils; Nicorandil; Patch-Clamp Techniques; Quinazolines; Verapamil | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Topics: Adverse Drug Reaction Reporting Systems; Androstenes; Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Germany; Humans; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Survival Rate; Thyroid Neoplasms | 2016 |
Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Quinazolines; Remission Induction; Tomography, X-Ray Computed; Withholding Treatment | 2017 |
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Hepatorenal Syndrome; Humans; Liver Failure; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Quinazolines | 2008 |
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Poly(D,L-lactic-co-glycolic acid) nanoencapsulation reduces Erlotinib-induced subacute toxicity in rat.
Topics: Animals; Dose-Response Relationship, Drug; Drug Compounding; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Lactic Acid; Materials Testing; Nanocapsules; Nanomedicine; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Rats; Rats, Wistar | 2009 |
Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Budgets; Carcinoma, Non-Small-Cell Lung; Centers for Medicare and Medicaid Services, U.S.; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Models, Economic; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Registries; Taxoids; United States | 2011 |
Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Withholding Treatment; Young Adult | 2011 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines | 2005 |
Comparison of the cardiac electrophysiological effects between doxazosin and bunazosin.
Topics: Animals; Arrhythmias, Cardiac; Cardiac Electrophysiology; Doxazosin; Drug-Related Side Effects and Adverse Reactions; Heart; In Vitro Techniques; Ion Channels; Quinazolines; Rats | 2008 |
New Zealand Committee on Adverse Drug Reactions: Tenth Annual Report 1975.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Child; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; New Zealand; Piperazines; Quinazolines | 1975 |